Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes
Author(s): Chris Wai Hang Lo , Yue Fei , Bernard Man Yung Cheung Added: 3 years ago

Prevention & Chronic Conditions
Late breaking Clinical Trial Data Addressing Cardiovascular Outcomes in Patients with Diabetes presented at American College of Cardiology Congress
Added: 1 week ago Source:  Radcliffe Cardiology, Greg Guillory
Two late-breaking clinical trials addressing cardiovascular outcomes in patients with diabetes were presented this week at the American College of Cardiology meeting in Atlanta, USA. One of these trials looked at the effects of the hyperactivation of the polyol pathway on diabetic cardiomyopathy (DbCM) and the other the effects of chelation therapy in patients with diabetes and prior myocardial… View more
AHA 23: Preventive Cardiology in 2023
Author(s): Michael Honigberg Added: 4 months ago
AHA 23 — Dr Michael Honigberg (Massachusetts General Hospital, US) highlights key 2023 cardiology updates, featuring novel data from AHA Scientific Sessions.Dr Honigberg provides commentary on the new SELECT trial outcomes and emphasises the incretin mimetic, semaglutide's role in cardiovascular medicine. He delves into lipid management with a focus on the CLEAR trial data and the incorporation… View more

Standards & Guidelines

Prevention & Chronic Conditions
Author(s): Thomas A Zelniker , Eugene Braunwald Added: 3 years ago
With progressive ageing and the growing incidence of obesity in the population, the prevalence of type 2 diabetes (T2D) has been rising rapidly and has become a major cause of death and disability worldwide.1 It is well established that atherosclerotic cardiovascular disease (ASCVD) and renal failure are responsible for a large majority of deaths in patients with T2D.2-4 Over the past decade, the… View more

Heart Failure
Jay Giri
Jay Giri

Author

Job title: Director of Peripheral Intervention
Dr Jay Giri is an Interventional Cardiologist, the Director of Peripheral Intervention at the University of Pennsylvania and Director of the Cardiovascular Catheterization Laboratory at the Corporal Michael C. Crescenz VA Medical Center in Philadelphia, and the Associate Director of the Penn Cardiovascular Outcomes, Quality & Evaluative Research Center. View more
Sodium–Glucose Cotransporter-2 Inhibitors and Heart Failure Prevention in Type 2 Diabetes
Author(s): Muhammad Shahzeb Khan , Javed Butler Added: 4 years ago
In 2008, the European Medicines Agency and US Food and Drug Administration (FDA) issued industry guidance stating that all future novel glucose-lowering agent trials must undergo routine cardiovascular risk evaluation either before approval or as a post-marketing commitment.1 This mandated that all cardiovascular endpoint committees prospectively adjudicate all major adverse cardiovascular events… View more

Heart Failure

Prevention & Chronic Conditions
Jafna Cox
Job title: Professor
Dr Jafna Cox obtained his MD in 1988 and trained in internal medicine at the University of Toronto. Following a fellowship in cardiology at Dalhousie University, Dr Cox completed post-doctoral training in health services research at the Institute for Clinical Evaluative Sciences in Ontario from 1993-1995. He returned to Halifax in 1995 and is currently the Heart and Stroke Foundation Endowed… View more
Katalon Recorder is recording ... Stop View more
Diabetes in Stage C Heart Failure
Author(s): Anjali Agarwalla , Jadry Gruen , Carli Peters , et al Added: 2 years ago

Heart Failure

Prevention & Chronic Conditions
ESC 22: ALL-HEART: Allopurionol in the Treatment of Ischaemic Heart Disease
Author(s): Isla Mackenzie Added: 1 year ago
ESC Congress 22 — Prof Isla S Mackenzie (University of Dundee, UK) reveals the findings of the ALL-HEART study, which aimed to evaluate the use of xanthine oxidase inhibitor, allopurinol- a drug reducing the production of uric acid-in patients over 60 with ischemic heart disease (IHD). 5,215 patients were included in the trial, and were randomized to receive either 600mg of allopurinol in… View more

Prevention & Chronic Conditions